Zydus Lifesciences Limited — Adalimumab Exporter Profile
Indian Pharmaceutical Exporter · #2 for Adalimumab · $66.8K export value · DGFT Verified
Zydus Lifesciences Limited is the #2 Indian exporter of Adalimumab with $66.8K in export value and 22 verified shipments. Zydus Lifesciences Limited holds a 5.6% market share in Adalimumab exports across 3 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Adalimumab Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Adalimumab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NEPAL | $66.7K | 20 | 99.9% |
| RUSSIA | $59 | 1 | 0.1% |
| ALGERIA | $19 | 1 | 0.0% |
Zydus Lifesciences Limited exports Adalimumab to 3 countries. The largest destination is NEPAL accounting for 99.9% of Zydus Lifesciences Limited's Adalimumab shipments, followed by RUSSIA (0.1%) and ALGERIA (0.0%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Adalimumab from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| D. K. M. PHARMACEUTICALS PVT. LTD. | NEPAL | $49.8K | 17 |
| D K M PHARMACEUTICALS PVT LTD | NEPAL | $17.0K | 3 |
| PSK PHARMA LTD | RUSSIA | $59 | 1 |
| ALGENPHARM | ALGERIA | $19 | 1 |
Zydus Lifesciences Limited supplies Adalimumab to 4 buyers globally. The largest buyer is D. K. M. PHARMACEUTICALS PVT. LTD. (NEPAL), followed by D K M PHARMACEUTICALS PVT LTD (NEPAL) and PSK PHARMA LTD (RUSSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Adalimumab Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $548.6K worth of Adalimumab through 223 shipments from 67 suppliers to 53 countries, serving 97 buyers globally. Zydus Lifesciences Limited contributes $66.8K to this total, accounting for 5.6% of India's Adalimumab exports. Zydus Lifesciences Limited ships Adalimumab to 3 countries through 4 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Adalimumab Exports?
Zydus Lifesciences Limited's average Adalimumab shipment value is $3.0K per consignment, based on 22 shipments totaling $66.8K. The largest destination is NEPAL (99.9% of Zydus Lifesciences Limited's Adalimumab exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Adalimumab Exporters?
Zydus Lifesciences Limited ranks #2 among 67 Indian Adalimumab exporters with a 5.6% market share. The top 3 exporters are RELIANCE LIFE SCIENCES PRIVATE LIMITED ($338.1K), ZYDUS LIFESCIENCES LIMITED ($66.8K), CADILA HEALTHCARE LIMITED ($37.5K). Zydus Lifesciences Limited processed 22 shipments to 3 destination countries.
What Adalimumab Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| EXEMPTIA 40MG INJECTION (ADALIMUMAB INJECTION 40MG/ 0.8ML) (BATCH NO. B400551 MFG.DT. 10/2024 EXP.DT. 09/2027) | $13.0K | 4 |
| EXEMPTIA INJECTION 1X1 PFS (ADALIMUMAB I | $11.3K | 5 |
| EXEMPTIA 40MG INJECTION ADALIMUMAB INJECTION 40MG 0 8ML BATCH NO B500114 MFG DT 02 2025 EXP DT 01 2028 | $9.9K | 2 |
| EXEMPTIA INJECTION 1X1 PFS ADALIMUMAB INJECTION 40MG 0 8ML BATCH NO B300006MFG DT 12 2022 EXP DT 11 2025 | $7.1K | 1 |
| EXEMPTIA INJECTION (ADALIMUMAB INJECTION40MG/ 0.8ML) BATCH NO. B400118 MFG.DT.02/2024 EXP.DT. 01/2027 | $6.9K | 2 |
| EXEMPTIA INJECTION (ADALIMUMAB INJECTION40MG/ 0.8ML) BATCH NO. B300661 MFG.DT.12/2023 EXP.DT. 11/2026 | $6.6K | 1 |
| EXEMPTIA 40MG INJECTION (ADALIMUMAB INJECTION 40MG/0.8ML) (BATCH NO. B500070 MFG.DT. 01/2025 EXP.DT. 12/2027) | $3.3K | 1 |
| EXEMPTIA 40MG INJECTION (ADALIMUMAB INJECTION 40MG/0.8ML) (BATCH NO. B500114 MFG.DT. 02/2025 EXP.DT. 01/2028) | $3.3K | 1 |
| EXEMPTIA INJECTION (ADALIMUMAB INJECTION | $2.1K | 1 |
| EXEMPTIA 40MG INJECTION (ADALIMUMAB INJECTION 40MG/0.8ML) (BATCH NO. B400612 MFG.DT. 12/2024 EXP.DT. 11/2027) | $1.7K | 1 |
Zydus Lifesciences Limited exports 13 distinct Adalimumab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EXEMPTIA 40MG INJECTION (ADALIMUMAB INJECTION 40MG/ 0.8ML) ( with 4 shipments worth $13.0K.
How Does Zydus Lifesciences Limited Compare to Nearest Adalimumab Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $338.1K | 20 | 10 | $16.9K |
| 2 | ZYDUS LIFESCIENCES LIMITED ★ | $66.8K | 22 | 3 | $3.0K |
| 3 | CADILA HEALTHCARE LIMITED | $37.5K | 4 | 1 | $9.4K |
| 4 | PHARMA CHOICE LLP | $26.7K | 23 | 4 | $1.2K |
Zydus Lifesciences Limited ranks #2 among 67 Indian Adalimumab exporters. Average shipment value of $3.0K compared to the market average of $8.2K. The closest competitors by value are RELIANCE LIFE SCIENCES PRIVATE LIMITED and CADILA HEALTHCARE LIMITED.
Which Indian Ports Ship Adalimumab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 55 | 24.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 47 | 21.1% |
| DELHI AIR CARGO ACC (INDEL4) | 23 | 10.3% |
| Bombay Air | 17 | 7.6% |
| DELHI AIR | 11 | 4.9% |
| Madras Air | 6 | 2.7% |
| HYDERABAD ACC (INHYD4) | 5 | 2.2% |
| AHEMDABAD AIR | 5 | 2.2% |
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Adalimumab Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Adalimumab, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Adalimumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Adalimumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 22 individual customs records matching Zydus Lifesciences Limited exporting Adalimumab, covering 13 formulations to 3 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 53+ countries, 97+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Adalimumab Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Adalimumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Adalimumab Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Adalimumab. For current shipment-level data, contact TransData Nexus.